BidaskClub Downgrades Amedisys Inc (AMED) to Sell
Amedisys Inc (NASDAQ:AMED) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Jefferies Group LLC restated a “buy” rating and set a $57.00 price objective on shares of Amedisys in a research note on Friday, April 28th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Wednesday, May 3rd. Royal Bank Of Canada restated a “hold” rating and set a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Finally, Stephens raised their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $56.50.
Amedisys (NASDAQ:AMED) opened at 48.56 on Friday. The firm has a market capitalization of $1.64 billion, a PE ratio of 41.50 and a beta of 0.89. Amedisys has a one year low of $34.58 and a one year high of $65.91. The stock has a 50 day moving average of $59.50 and a 200-day moving average of $54.23.
Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 EPS. On average, equities analysts predict that Amedisys will post $2.21 EPS for the current year.
In related news, Director Bruce D. Perkins bought 500 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were purchased at an average cost of $59.69 per share, with a total value of $29,845.00. Following the completion of the transaction, the director now directly owns 13,331 shares of the company’s stock, valued at $795,727.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Lawrence R. Pernosky sold 11,500 shares of the stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $58.97, for a total value of $678,155.00. Following the completion of the sale, the insider now directly owns 30,093 shares in the company, valued at $1,774,584.21. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock worth $1,954,125 over the last ninety days. 2.80% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Swiss National Bank raised its stake in shares of Amedisys by 1.8% in the first quarter. Swiss National Bank now owns 44,300 shares of the health services provider’s stock valued at $2,263,000 after buying an additional 800 shares in the last quarter. Comerica Bank raised its stake in shares of Amedisys by 4.2% in the first quarter. Comerica Bank now owns 30,909 shares of the health services provider’s stock valued at $1,670,000 after buying an additional 1,258 shares in the last quarter. Suntrust Banks Inc. raised its stake in shares of Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock valued at $279,000 after buying an additional 107 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Amedisys by 125.0% in the first quarter. Bank of New York Mellon Corp now owns 781,256 shares of the health services provider’s stock valued at $39,915,000 after buying an additional 433,956 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock valued at $61,347,000 after buying an additional 717,939 shares in the last quarter. 99.80% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.